Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

1-1-2019

Average Time To Negativity Of New Alere Ultra-Sensitive Rapid
Diagnostic Test After Treatment For Malaria.
Azan Zahir Virji
azan.z.virji@gmail.com

Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl
Part of the Public Health Commons

Recommended Citation
Virji, Azan Zahir, "Average Time To Negativity Of New Alere Ultra-Sensitive Rapid Diagnostic Test After
Treatment For Malaria." (2019). Public Health Theses. 1901.
https://elischolar.library.yale.edu/ysphtdl/1901

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar –
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information,
please contact elischolar@yale.edu.

Average time to negativity of new AlereÔ ultra-sensitive rapid
diagnostic test after treatment for malaria.

A thesis presented to:
The Department of Epidemiology of Microbial Diseases
Yale School of Public Health

In partial fulfillment of the requirements for the degree of:
Master of Public Health (MPH)

By:
Azan Zahir Virji

May 2019

Advisor/Committee Chair: Sunil Parikh, MD, MPH
Committee Members: Amy Bei, PhD

Abstract
Malaria remains one of the most challenging infections globally. Malaria RDTs have had the
largest impact on malaria detection in recent years with almost 245 million RDTs delivered
globally. (1) They work by detecting either the histidine-rich protein (HRP2) or the Plasmodium
lactate-dehydrogenase (pLDH). (2) Following a malaria infection, the HRP2 and pLDH antigens
often circulate in the blood stream for several weeks. (3) As new RDTs are constantly being
developed, each with a better sensitivity, specificity and lower limit of detection than its
predecessor, the need to understand the persistence of their positivity, following a malaria
infection, remains. The latest RDT on the market is produced by Alere™ and is called the ultrasensitive RDT (uRDT). To test how long this new RDT remains positive following a malaria
diagnosis and treatment, we prospectively followed children for 42 days. Children were either
HIV positive or negative and either placed on a 3-day or 5-day artemether-lumefantrine regimen.
Microscopy and the uRDT were performed on days 0, 7, 14, 21, 28, 35, and 42. The mean length
of uRDT positivity was 9.2 days with a standard deviation of 11.3 days. Approximately 50% of
all uRDTs remained positive for 11 days post treatment of malaria. Neither HIV status nor AL
duration impacted the length of uRDT positivity. Only parasite density was directly correlated
with uRDT positivity with an increase in parasite density of 1 parasite/µl resulting in 0.6
additional days of uRDT positivity. Microscopy (considered the gold standard in our study) and
uRDT outcomes matched 67.5% of the time (320/474). The true positive rate (sensitivity) was
calculated to be 91.3% and the true negative rate (specificity) was 55.3%. The uRDT was also
able to predict treatment failure in children 7 days prior (p = 0.015). Due to its positive
persistence that can lead to false positive, we recommend that the use of Alere’s uRDT be
limited to low transmission and elimination settings only.
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Introduction
Malaria remains one of the most challenging infections globally. In 2017, it is estimated that
there were approximately 219 million cases with 435,000 deaths. The global community has
made significant strides in malaria control over the past 2 decades, with most of the strides
resulting from improved case detection, treatment, and prevention with bed nets. However,
recent years have seen these gains stagnate or reversed in many areas. The 10 highest burden
countries reported increases in malaria cases with over a half a million more cases in Nigeria,
Madagascar and the Democratic Republic of Congo. (1) Efforts to thwart the spread of the
disease have relied predominantly on improved diagnosis and treatment of patients (4). Getting
back on track to achieve the 2025 milestones, will require a concerted effort to expand our
malaria detection capabilities and ensure no case goes untreated.
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Currently, three main methods of malaria parasite detection are employed: 1) light microscopy of
stained blood smears for physical observation of parasites; 3) nucleic acid amplification methods
of parasite DNA; 3) immunochromatographic tests, such as rapid diagnostic tests (RDTs) or
rapid antigen tests (RATs) for detection of parasite proteins. Each method of diagnosis presents
its own advantages and challenges.

Light microscopy
Since its development in 1904, light microcopy following Giemsa or Wright staining of thick or
thin blood smears, has remained the most suitable and convenient diagnostic method for malaria.
(5) In 2017, 25% of all malaria diagnosis was done using light microscopy. (1)

Following the initial purchase of a microscope (~$300) each malaria smear is relatively
inexpensive (~ $0.12-$0.40). (5, 6). While most microscopes still need electricity, the invention
of high-quality light emitting diodes (LED) illumination and solar battery chargers has made
microscopy more feasible in remote areas. (5) Moreover, microscopy is also able to differentiate
between malaria species and quantify parasitemia. (5) (Supp. Fig. 1)

However, light microscopy is still limited by its need for well-trained microscopists and its
relatively poor diagnostic sensitivity. (4, 5) Skilled personnel are required to properly prepare
smear slides. Low-quality blood film generation can lead to artifacts, such as bacteria, fungi,
stain precipitation and cell debris, being commonly mistaken for malaria parasites. (5)
Additionally, failure to distinguish between P. falciparum from P. vivax, the two most common
species, is frequent, underreported and due to poor training. (5) Currently, the limit of detection
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(LOD) for microscopy is estimated to be between 4-20 parasites/µl in lab settings and 50-100
parasites/µl in field settings, a threshold that is likely higher in areas with inadequate equipment
and poorly-trained microscopists. (4, 5) As efforts to improve malaria microscopy ramp up, it
continues to remain the gold-standard for confirmation of an active infection, especially in lowresource settings. (4, 5)

Nucleic acid detection
Molecular methods to diagnose malaria include end-point polymerase chain reaction (PCR), realtime quantitative polymerase chain reaction (qPCR) or the more recently optimized method,
Loop-mediated isothermal amplification (LAMP) (7). PCR for malaria detection relies
predominantly on the detection of the 18S RNA gene because it is specific, conserved in all
Plasmodium species, and has ~5-7 copies per genome making it a highly sensitive test. (8) DNA
targets for PCR have also been developed but are considered inferior because the circulation of
DNA post-infection can lead to false positives. (9) On average, the threshold for detection for all
PCR based methods is 0.1-5 parasites/µl. (8-10) With the requirement of only 5µl of blood, PCR
is by far the most accurate method of malaria parasite detection.

Despite its high diagnostic accuracy, one the biggest challenges with PCR is its cost and inability
to be performed at point of care (POC). (10) However, LAMP may offer a practical alternative.
Designed by the Foundation for Innovative New Diagnostics, Switzerland, and Eiken Chemical
Co., Ltd., Japan, the vacuum-dried reagents that are stable at ambient temperature allow LAMP
to be used in resource-constrained settings. (10) Like PCR, it also amplifies nucleic acids (LOD
0.2-2 parasites/µl) but uses simpler equipment, such as a heat-blocks instead of a thermocycler
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and is less time intensive than regular PCR. (10-12) Furthermore, LAMP reagents are also
cheaper than conventional PCR reagents ($0.40-$0.70 and $1.50-$4 respectively). (9) Although
no quantitative results can be derived from LAMP and results must be read with the naked eye
using a UV light, LAMP is a promising method of POC diagnosis of malaria. (9, 11, 12) (Supp.
Fig 1)

A study to test the performance of LAMP kits in a remote clinic in Uganda highlighted two key
insights: 1) that a sensitivity similar to that of a nested PCR in a United Kingdom reference
laboratory (with a qualitative reading by gel) could be achieved using LAMP in the field setting
and 2) technicians without previous molecular training could reliably perform LAMP following a
short training period (10, 12). However, even though the LAMP reactions proceed at a much
lower temperature of ∼60°C compared to PCR, electricity is still needed to run the test creating a
barrier to point of care detection (13).

Rapid diagnostic tests
Malaria RDTs have had the largest impact on malaria detection in recent years. In 1990, the first
malaria RDTs were introduced to overcome the practical challenges of microscopy with over 60
manufacturers supplying the tests by 2005 (14). In 2017, almost 245 million RDTs were
delivered globally. (1) A large majority of these RDTs (66%) were capable of only detecting P.
falciparum and were delivered to the WHO African Region (1). Today, the WHO recommends
that all clinically suspected cases of malaria be confirmed either through the use of microscopy
and/or RDT, both of which should be available at testing sites (15).
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Malaria RDTs work by detecting either the histidine-rich protein (HRP2), only found in
Plasmodium falciparum, or the Plasmodium lactate-dehydrogenase (pLDH) found in all
Plasmodium sp. (2). The HRP2 is a water-soluble protein produced by trophozoites and young
(not mature) gametocytes whereas pLDH is produced by both asexual and sexual stages of
malaria parasites. (16) Following a malaria infection, the HRP2 and pLDH antigens often
circulate in the blood stream for several weeks. (3) A study modelling the length of RDT
positivity found that 50% of treated individuals would still present a positive HRP2 RDT after 15
days (5-32 95% CI) and a positive pLDH RDT after 2 days (1-7 95% CI). (7, 17, 18). This often
misconstrues whether or not a new infection is present and can lead to a false positive malaria
diagnosis, particularly in settings where transmission intensity is high. Similarly, cross reaction
with other infections such as schistosomiasis and trypanosomiasis can also occur in areas where
these diseases are prevalent. (19, 20).

Another limitation of RDTs includes the number of false negatives due to deletions of the HRP2
gene or parasitemia levels below the LOD (7, 21-23). In 2010, malaria parasites with the pfhrp2
gene deletion were confirmed in the Amazon Basin in Peru. (23) Since then, multiple reports
have confirmed false negatives and pfhrp2 PCR-negative parasites in 9 countries across the
African continent. (24, 25) In Mozambique, a molecular surveillance study found that out of the
69 individuals who were RDT negative but microscopy positive, only one (1.45%) had a pfhrp2
deletion. (24) False negatives can also be caused by poor transport and storage with sustained
exposure to high temperatures (23) (Supp. Fig 1)
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In spite of these limitations, RDTs are an inexpensive ($0.45-$1.50) and highly effective way of
detecting malaria in a relatively short period of time (5-20 mins), with limited-training and in
low prevalence areas (5, 7, 9, 18). A meta-analysis of RDTs estimate an average sensitivity and
specificity of 95.0% (95% CI: 93.5-96.2%) and 95.2% (95% CI: 93.4-99.4%) respectively for
PfHRP2 (7). RDTs detecting Pf-pLDH report a marginally lower sensitivity of 93.2% (95% CI:
88.0–96.2%) but higher specificity of 98.5% (95% CI: 96.7–99.4%) (7). With an overall LOD of
approximately 5-200 parasites/µl and no need for laboratory infrastructure, RDTs are considered
a quick yet accurate method of detecting malaria even in remote settings. (3, 26)

Ultra-sensitive RDT
New RDTs are constantly being developed, each with a better sensitivity, specificity and LOD
than its predecessor. The latest RDT on the market is produced by Alere™ and is called the
ultra-sensitive RDT (uRDT).

Using the same volume of blood (5-15µl) and the same immunochromatographic cassette as
other RDTs, the uRDT is supposedly 10 times more sensitive than current malaria RDTs with a
lower LOD of 0.1-100 parasites/µl (2, 27, 28). The uRDT differs from the Standard Diagnostics,
Inc. BIOLINE Malaria Ag P.f RDT (SD-RDT) since it uses carboxyl-modified and biotinylated
latex fragment antibodies (FAbs) and polystreptavidin on the test line (26). However, both the
uRDT and the SD-RDT use lateral flow and 5 µL of whole blood specimen (WBS) (26, 28, 29).

When compared to a widely used SD- RDT, the uRDT has shown an increased sensitivity in
detecting asymptomatic parasitemia (29, 30). Using qPCR as the gold standard, the uRDT had a
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sensitivity of 84% while the SD-RDT had a sensitivity of 44% in the high-transmission setting of
Uganda. On the other hand, the uRDT had a sensitivity of 62% and the SD-RDT had a sensitivity
of 0% in the low-transmission setting of Myanmar. (30)

Alere’s uRDT will undoubtedly serve as a useful tool in the elimination of malaria in low
transmission areas. However, it is likely that as the advantages of the uRDT become more
apparent, it will slowly replace other RDTs, even in high transmission settings. In anticipation of
this, we set out to understand how long the uRDT remains positive for post anti-malarial
treatment and compare the uRDT to microscopy in the malaria endemic setting of Uganda. Since
the HRP2 antigen circulates in the blood following a malaria infection, it is likely that the uRDT
will remain positive for an extended period of time post-treatment and result in a large number of
false positives. To test this hypothesis, a longitudinal cohort of children in Tororo, Uganda who
were either HIV positive or HIV negative, were placed on a 3-day or a 5-day ArtemetherLumefantrine (AL) combination therapy and followed prospectively for 42 days. A uRDT and
microscopy test were performed at regular 7-day intervals between day 0-42. Time to negativity
for the uRDT was analyzed and whether HIV status or duration of AL therapy had any impact on
this time. Finally, we assessed if the uRDT was able to pick up treatment failures (TFs) in
children before they occurred.

12

Materials and Methods

Study site
Uganda is among the 15 countries most affected with malaria in the world with the predominant
malaria species being Plasmodium falciparum (31). Of the 16 countries globally that are
responsible for 80% of the global malaria burden, Uganda ranks fourth (1). The country has an
annual rainfall of 1,000 – 1,500 mm typically between the two rainy seasons (March – May and
August – October) (32). Between 2016 and 2017, Uganda saw an increase in 25% of reported
malaria cases (8,600,724 cases with 14,390 malaria-related deaths in 2017) (1). Seven percent of
all deaths in children under 5 and 11% of all deaths in post-neonates were due to malaria in
2016. (33) The average malaria parasite prevalence in Uganda is 45% and follows a perennial
transmission pattern (34, 35). Hospital records predict that 30-50% of all outpatient visits and 914% of all inpatient deaths are due to malaria (34).

Tororo is located in a savannah grassland at an elevation of 1,185 m above sea level in Eastern
Uganda (32). Maize and rice form the staple of the diet and are grown on low-lying wetlands, a
perfect breeding ground for mosquitoes (31, 32). The major mosquito species that dominate the
region include Anopheles gambiae s.s. and Anopheles funestus with some Anopheles arabiensis
(32). In 2012, Tororo had the highest burden of malaria in the country of Uganda with a
Plasmodium prevalence of 48% (31). The annual entomological inoculation rate (aEIR)
for Plasmodium falciparum transmitted by Anopheles gambiae in 2012 was 125 (95% CI: 72.2 –
183.0) (32). The most recent estimate in 2015 puts the malaria parasite prevalence in Tororo at
18%. (36)
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Busia sits under Tororo at an elevation of 1,198m with half of the district crossing the border into
Kenya (37). Across Uganda, mortality due to severe malaria is highest in Busia (38). With a
meager population of 55,958, Busia saw almost 54,652 P. falciparum cases of malaria in 2015
out of 7,111,817 cases across the country of Uganda. (39, 40)

The study was conducted in the eastern region of Uganda in the Tororo and Busia districts at the
Tororo District Hospital (TDH) or Masafu General Hospital (MGH) between February and
December 2018. (Fig. 1)

Study methodology
Our study was done in the context of an NIH-funded trial, named Extended Duration ArtmetherLumefantrine (AL) Treatment for Malaria in Children (EXALT), a collaboration between Yale,
University of California San Francisco (UCSF) and the Infectious Disease Research
Collaboration (IDRC). This parent study is a prospective cohort study looking at the
pharmacokinetic and pharmacodynamic changes following an extended duration of AL in HIVinfected children on EFV and HIV-uninfected children.

Enrollment consisted of 160 children, aged 3-10 years who were HIV positive (HIV+) and on
EFV-based ART, in addition to 220 children aged 6 months-10 years who were HIV negative
(HIV-). Inclusion criteria included: 1) residency within 60 km of the study clinics; 2) Weight ³ 6
kg; 3) A microscopically and clinically confirmed case of uncomplicated P. falciparum malaria;
4) Provision of informed consent and willingness to return to the clinic for evaluations.
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Within each group, based on HIV status, children were randomized to either a 3-day AL therapy
or a 5-day AL therapy. They were then followed for 42 days following their initial malaria
diagnosis to assess the incidence of a recurrent malaria episode. The two main primary outcomes
were the measurement of the plasma concentration of all drug analytes (independent variables)
and the recrudesce or new infection of malaria (dependent variable).

For the independent variable (pharmacological evaluation of artemether and lumefantrine),
capillary sampling (200 µl) and venous sampling was done between 0.5-8 hours postadministration of the 6th AL dose in the 3-day group and the 5th AL dose in the 5-day group and
on days 8, 14, and 21 for all groups. For the dependent variable, microscopy was done and dry
blood spots (DBS) for LAMP were collected at days 0, 7, 14, 21, 28, 35 and 42. Since LAMP
analysis was performed later, microscopy and clinical symptoms were used to decide treatment
outcomes. Treatment outcomes were defined as per the standard WHO classification system:
Early Treatment Failure (ETF), Late Parasitological Failure (LPF), Late Clinical Failure (LCF)
and Adequate Clinical and Parasitological Response (ACPR). (Supp. Fig. 3) Early or late
clinical failures within 14 days were considered as recrudescent parasites and were treated with
quinine. Clinical failures between days 15-42 were treated as a new episode of malaria. AL was
re-prescribed for these new episodes and, if eligible and consenting, these children were reenrolled in the study.

Our sub-study to understand the length of uRDT positivity utilized the data collected from the
EXALT parent study. In addition to the parasite density on day 0 and every 7 days thereafter
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from the EXALT study, we administered a uRDT at each time point. While DBS were taken at
each time point, this study did not perform LAMP and instead used the microscopical evaluation
as the gold standard for diagnosis of malaria and treatment outcomes.

Human subjects research
Parents/guardians made the decision to enroll their child in the study. Study physicians were
responsible for the informed consent discussion in the clinic. All conversations were done in the
appropriate language for the adult parent/guardian and both written and verbal consent was
required. If the parent/guardian was unable to read or write, their fingerprint was taken as a
substitute for their signature. For blood specimens that were collected from children, permission
for specimen banking and future use of biological specimens was also included in the consent
process.

Once verbal and written consent were attained, a series of evaluations such as a detailed history,
physical examination and measurements of temperature, height and weight were taken. Blood
was then collected for hemoglobin testing and malaria thick and thin smear to decide if the
participant was eligible for study enrollment. If enrolled, parents/guardians were instructed to
return on a specified follow-up day; if they failed to return on that day, a home visitor was sent to
encourage them to return to the clinic (active follow-up).

Other considerations were that all HIV-infected children were maintained on anti-retroviral
therapy (ART) throughout the course of the study. Moreover, parents were allowed to withdraw
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their children from the study at any time and anonymity of participants was preserved even
during analysis.

Clinical and laboratory evaluations

Microscopy
Thick smear blood slides were obtained from capillary finger-pricks and parasite density was
counted by the laboratory technicians at the time of presentation. The density was estimated by
counting the number of asexual parasites per 200 leukocytes, assuming a leukocyte count of
8000/µl (or per 500 leukocytes, if the count is <10 asexual parasites/200 leukocytes). Smears
were considered negative if examination of 100 high-powered fields did not reveal parasites. If
the thick blood smear was positive, the patient was diagnosed with malaria. If the smear was
negative, the patient was managed by medical officers at their usual clinic. All subjects positive
for P. falciparum and with an uncomplicated case were referred to the study medical officers to
determine further eligibility for study enrollment. Double readings on all smears were done to
ensure accuracy and any discrepancies were resolved by the head laboratory technician.

Rapid diagnostic test (RDT)
At every time point, including at enrollment (time=0), a microscopic slide was read and an
AlereÔ Ultra-Sensitive Rapid Diagnostic Test (Reference number: 05FK140, Test lot number:
05LDB001A, Sub: A, Diluent lot number: 05BDDA145, Manufacture date: January 2018 Expiry
date: December 2019) was performed. Assay diluent was then added and the uRDT was left for
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20 minutes before being read. (Supp. Fig. 2) RDT results were read only once and recorded as a
binary variable

Loop-mediated isothermal amplification (LAMP)
LAMP Assays were performed using LoopampÔ MALARIA Pan/Pf Detection Kit (Eiken
Chemical Company, Japan) (41). A DBS of finger-prick blood was also made on cellulose filter
paper at each time point (Whatmanä 1001-090 Grade 1 Qualitative Filter Paper, Diameter: 9cm,
Pore Size: 11µl). All DBS were kept at 4 °C in our laboratory in Tororo, Uganda. Although
Uganda has the capacity to perform LAMP analysis, all samples were analyzed at the Yale
School of Public Health, Laboratory of Infectious Diseases, New Haven, Connecticut, 4 months
later. DBSs were analyzed in batches of 25 and DNA was extracted using reagents included in
the LAMP kits. The tubes, along with positive and negative controls, were placed into the LF160 LAMP incubator (Eiken) with a maximum of 16 tubes at one time. All samples were
incubated for 40 minutes at 65 °C, then at 80 °C for 5 minutes. Results were read by a single
individual observed for florescence by placing each tube under a UV light.

Data management and statistical analysis
All data was collected on standardized case record forms (CRFs) by study physicians. Lab
results were recorded first in the laboratory record book and then transferred over to the CRFs.
Study coordinators reviewed the CRFs regularly for completeness and accuracy. Once all forms
were complete, data was double entered onto a computerized database to verify accuracy. Data
was then archived to a large-scale digital tape daily and once a month, a complete backup of the
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tape was transported off-site to the Kampala Data Management Center (DMC) where it was
uploaded to an online secure server for read-only access.

From the secure server, data was downloaded as a Microsoft Access database and then exported
to Microsoft Excel for cleaning. Subjects with one or more missing data point (for parasite
density or uRDT outcome) were removed and excluded from the analysis. In Excel, the
proportion of all uRDTs that were positive at each time point, for ACPR children only, were
plotted with an exponential line of best fit. This graph was then stratified based on HIV status
and AL therapy assigned. Next, data was imported into SPSS (IBM Corp. Released 2016. IBM
SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.) where a Mann-Whitney
independent t-test was run to decipher if HIV status or AL regimen impacted the length of uRDT
positivity. To confirm which variable was correlated with time to uRDT negativity, a linear
regression was run with parasite density, age, HIV status and duration of AL therapy as
independent variables and time to uRDT negativity as the dependent variable. Lastly, a chisquare analysis was performed to study the agreement between microscopy and uRDT outcome
as well as the ability of the uRDT to predict a TF.
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Results

Patient demographics
Between 21st of February 2018 and 12th of December 2018, 305 children were screened at MGH
hospital. Of these children, 26.6% met the inclusion criteria (81 children). (Fig. 2) The most
common reasons for exclusion included the following: negative blood smear, mixed infection
with non-falciparum species, complicated/severe case of malaria, prior anti-malarial use, lack of
access to uRDT at the time of enrollment and decline of study participation. The mean age of the
study participants was 6 months (Range: 2 months to 16 months). Twenty children were HIV
positive and 61 were HIV negative. Lastly, the sample was split with 57% of all children on a 3day AL regimen and 43% on a 5-day AL regimen.

Treatment outcomes of enrolled participants
Initial parasite density of enrolled participants ranged from 64 parasites/µl to 205360 parasites/µl
with an average of 41520 parasites/µl. (Fig. 2) Of the 81 enrolled children, n=26 experienced an
adequate clinical and parasitological response (ACPR), n=21 experienced a late clinical failure
(LCF) with fever and a positive smear between days 4-42 post-treatment, and n=34 experienced
a late parasitological failure (LPF). Overall, 67.9% of all children experienced a TF.

Persistence of positive uRDT after treatment with AL
To analyze the length of uRDT positivity following treatment for microscopically-confirmed
malaria infection, only individuals who experienced an ACPR were considered. Children with
LPF or LCF, by definition, presented with parasites detected by microscopy during follow-up
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and therefore were excluded from this analysis to avoid impacting the overall line of best fit. Of
the 26 children with an ACPR, only 21 children had a uRDT result at every time point during the
42-day follow-up period. The remaining 5 children, who had one or more missing uRDT result
during the 42-day period, were excluded from the analysis.

Initially, the proportion of uRDTs that were still positive at each time point was graphed. Data
points from all 21 ACPR children were included in this curve regardless of whether they were
HIV+, HIV-, on a 3-day AL regimen or on a 5-day AL regimen. (Fig. 3a)

The mean length of uRDT positivity among these 21 children was 9.2 days with a standard
deviation of 11.3 days. Using the best-fit regression line, with an R2 of 83.3%, it can be seen that
approximately 50% of all uRDTs will remain positive for 11 days post treatment of malaria.
Similarly, 21 days post effective treatment of malaria, 25% of all uRDTs will still be positive. A
visual portrayal of these results for each participant is shown in Figure 3b. Six individuals (ID:
50082, 50069, 50107, 50086, 50109, 50134) had a positive uRDT result after a negative uRDT
result was recorded at least 7 days prior even though their microscopy result was negative at both
points.

Duration of uRDT positivity based on antimalarial treatment regimen and HIV status
Using the 21 children described above, we plotted the proportion of all uRDTs that were positive
at each time based on regimen of AL therapy that they received (3-days or 5-days) and their HIV
status (positive or negative). Our sample had 10 participants who were on a 3-day AL regimen
and 11 participants who were on a 5-day regimen. A regression line of best fit to approximate the
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two sets of data points had an R2 value of 92.2% for the children on AL for 3 days and 76.6% for
children on AL for 5 days. A simple extrapolation showed that 50% of children still had a
positive uRDT on day 8 for those on 5-day AL therapy as opposed to day 14 for those on 3-day
AL therapy. (Fig. 4) A visual representation of the uRDT outcome at each time point for each
participant stratified by AL regimen is shown in Supplementary Figure 4. A Mann-Whitney ttest was done to compare the mean time of uRDT positivity of the 3-day and 5-day group. No
significant difference was found in the length of uRDT positivity (p = 0.416). This association
was later corroborated in the linear regression model (p = 0.877). (Fig. 6)

Similarly, the analysis described above was repeated on 5 HIV+ and 16 HIV- children. (Fig. 5 &
Supp. Fig. 5) Half of all uRDTs still returned a positive outcome on day 6 for HIV- children and
day 13 for HIV+ children using the approximate trend line. This difference in uRDT length of
positivity between HIV positive and negative children was not significant (p = 0.655 from t-test
and p = 0.715 from linear regression model). (Fig. 6)

Additional analysis using a linear regression model also suggested that duration of AL therapy or
HIV status were not significantly associated with a possibility of treatment failure by day 42.
(Fig. 7) Treatment failure was classified as an LCF or an LPF by day 42. The p value for the AL
regimen was 0.276 and that for HIV status was 0.779. This analysis was repeated with a chisquare crosstabulation and the same non-significant association for AL therapy, HIV status and
treatment outcome was seen. (Supp. Fig. 6 & 7)
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Parasite density and length of uRDT positivity
Using all the 21 children with a uRDT at all time points, we performed a linear regression
analysis to determine the correlation between parasite density at day 0 and length of uRDT
positivity. (Fig. 6) Age, HIV status and duration of AL therapy were included in the analysis as
potential confounders and were added individually to the regression model.

A significant association was found between initial parasite density how long it takes for the
uRDT to turn negative (p = 0.006). Since parasite density and uRDT length of positivity were
both modelled as continuous variables, the standardized beta coefficient suggests that an increase
in parasite density of 1 parasite/µl results in 0.6 additional days of uRDT positivity. Of all
confounders, age was found to have the greatest impact on the beta coefficient reducing it from
3.807 to 3.381. Another linear regression model found no significant correlation between initial
parasite density and the likelihood of TF (p = 0.402). (Fig. 7)

Microscopy and uRDT concordance
Concordance between microscopy and uRDT was assessed using a chi-square test of
independence. Data from all time points where both a parasite density measure and an uRDT
result were available were included in this analysis. Parasite density was converted into a binary
categorical variable. (Fig. 8)

Of the 4 possible combinations (uRDT positive/parasites present, uRDT positive/parasites
absent, uRDT negative/parasites present and uRDT negative/parasites absent) the parasite
density and uRDT outcome matched 67.5% of the time (320/474). The true positive rate
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(sensitivity) was calculated to be 91.3% and the true negative rate (specificity) was 55.3%.
Twenty nine percent of the time, the uRDT was positive but the smear was negative (n=140), and
the reverse was true only 0.03% of the time (n=14). We were able to reject the null hypothesis of
independence and conclude that the parasite density and uRDT outcome are significantly
correlated with one another (p = 8.71e-23). In other words, the odds of the uRDT being positive
given that microscopy also detects parasites is 12.98 (CI: 7.18 - 23.45).

uRDT as a predictor of treatment failure
Due to the uRDT’s highly sensitive nature and ability to detect parasitemia at lower limits of
detection, we hypothesized that the uRDT could be used to indicate a possible treatment failure
(LCF or LPF), by becoming positive prior to microscopy. Our initial sample consisted of 21 LCF
and 34 LPF participants. However, after excluding subjects with missing data, 17 LCF and 33
LPF were left. Treatment failure (TF) was detected at various point throughout the 42-day period
with 1 participant failing on day 14, 19 participants failing on day 21, 14 participants failing on
day 28, 7 participants failing on day 35 and 9 participants failing on day 42.

Regardless of when the treatment failure was recorded (as determined by microscopy +/- fever),
we compiled all participants in a table with the day of failure denoted as “Day F” (Fig. 9) The
uRDT outcome on day F was portrayed alongside the uRDT outcome 7 days prior to when TF
was designated (F-7) and 14 days prior to when TF was designated (F-14). Of all TFs,
irrespective of the day, 54% had a positive uRDT only 7 days before TF and 34% had a positive
uRDT both 7 days and 14 days prior to TF. To test the significance of this association, we
performed a Fisher’s exact test to account for the small cell sizes. (Fig. 10) A two-sided test
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suggested that the uRDT on day F and the uRDT on day F-7 were not independent and instead
significantly associated with one another (p = 0.015). Repeating the Fisher’s analysis for the
relationship between uRDT on day F and day F-14 was not significant at an alpha of 5%.

Discussion

Alere’s™ ultra-sensitive RDT has revolutionized malaria detection particularly in low
transmission and elimination settings. However, its increased sensitivity comes with challenges
in field settings, such as false positives relative to microscopy, a direct result of its continued
positivity following a malaria infection.

A recent literature review on the persistence of positivity of RDTs after anti-malaria treatment,
by Dalrymple et al., showed that when using an HRP2-RDT, 50% of patients present a negative
test by day 19 (CI: 10-31) when an ACT is given on day 0. (3) Our findings on the uRDT
suggest that it takes 11 days, well within the 95% confidence interval. Similarly, a prospective
cohort study of 32 pregnant women found that 41% of women still returned a positive HRP2RDT at day 7 after microscopy+RDT diagnosis and prescription of an ACT. (42) In some
instances, PfHRP2-RDTs have shown a positive result more than 5 weeks after antimalarial
treatment (with parasite clearance confirmed by microscopy). (43) Studies on post-treatment
HRP2 degradation suggest a first-order exponential decline with a median half-life between 3.04.7 days in different African countries. (44) Our study aligns with all these prior studies and
provides additional compelling evidence about one of the biggest challenges of HRP2-RDTs- the
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extended period of time that the RDT remains positive even after treatment and elimination of
the parasite.

While our study did not incorporate other RDTs, it has been shown that pLDH-RDTs remain
positive for significantly less time (50% present as positive between 1-7 days post-treatment). (3)
Therefore there may be a benefit to limiting HRP2-RDTs to low transmission settings and
pLDH-RDTs to high transmission settings, but this suggestion would need to be tested further.
All in all, any RDT test result must be confirmed with either microscopy or PCR to account for
antigen persistence, a recommendation in line with current WHO guidelines.

We hypothesize that the 6 individuals described earlier, who were ACPR and that had a positive
uRDT result after a negative uRDT result, likely arose due to simple random error. Three out of
the six individuals had the positive uRDT on day 35 or 42. Therefore, the other possibility is that
the uRDT was picking up a treatment failure that was imminent. Since our follow-up period
ended on day 42, the only way to confirm this hypothesis is by performing LAMP tests at those
time points.

No significant difference was seen in length of uRDT positivity between HIV positive and
negative individuals. However, this effect may have been dampened by the small sample size of
HIV positive children in our study. In fact, for HIV+ children, it took an additional 7 days before
50% of all the tests were no longer positive. HIV has been shown to directly and adversely
impact the response to malaria. (45) Due to their impaired immune system, HIV+ individuals
produce lower levels of interferon g and tumor necrosis factor in response to malaria parasites.

26

(45) This could lead to higher parasite burdens, longer circulation of the HRP2 antigen and
longer positivity of the uRDT. Similarly, while we did not see a significant association between
course of AL therapy and length of positivity, this may have also been due to a small sample
size. Theoretically, however, this was expected. Multiple studies have confirmed that the parasite
clearance half-life (PC1/2) is 1.8 to 3.0 hours for a 3-day artesunate therapy. (46) Taking a longer
treatment course is unlikely to impact how long parasites remain in the body and the HRP2
antigen presence.

Participants who enrolled in the study with higher parasitemia were found to have longer
persistence of the HRP2 antigen, a finding also reported previously. (47) We hypothesize this is
because of a higher proportion of remaining parasites following initial AL treatment however
PCR analysis would have to confirm this. Interestingly, a recent study suggested that artesunate
clears non-ring stage parasites by a process known as “pitting” where the parasite is expelled, the
erythrocyte is resealed and then returned into circulation. (48) Additionally, the HRP2 antigen,
that is present in the cytosol of the erythrocyte soon after parasite invasion, continues to be
expressed on the erythrocyte membrane even after the parasite is expelled. (48) Thus, a higher
initial parasitemia is likely to lead to more pitted and HRP2 covered erythrocytes. These revived
erythrocytes have a reduced lifespan of 1-4 weeks which would explain why the uRDT remains
positive for an extended period of time post-treatment.

In the same study by Dalrymple et al. cited earlier, children and those subjects on artemisinin
combination therapies (ACTs) demonstrated greater persistence of the HRP2 antigen through
longer RDT positivity compared to adults or subjects on other antimalarials (artemisinin
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monotherapy, chloroquine, quinine, primaquine, sulfadoxine-pyrimethamine and mefloquine)
(3). While we did not look at the effect of other antimalarials, age was shown to be the strongest
confounder in our study. In our linear regression model, age had a standardized beta coefficient
of -0.226 suggesting that every increase in age by 1 year would result in a decrease in the time to
uRDT negativity by 0.226 days. Although this association was not significant, it follows the
same direction as reported in previous studies. One plausible reason behind this relationship is
that children who are younger are less likely to have developed an acquired immunity through
repeated malaria infections. (49, 50)

We expected a longer course of AL therapy to prevent recrudescence of the malaria parasite or
prevent a new infection. This is because artemisinin and its derivatives have a plasma half-life of
<3 hours and its partner drugs, lumefantrine, has a half-life of 5 days. (51) It was no surprise to
find that 98% of all TFs occurred on day 21 and beyond, when the drug concentrations are below
a potent concentration. However, we did not see a reduction in TF due to a longer AL regimen as
anticipated. Although we were only looking at the association between the outcome on day 42,
the pharmacodynamic results from the EXALT study will shed definitive light on the impact of a
longer AL regimen.

Even though a significant association between microscopy and the uRDT was found, 29.54% of
the time the uRDT was positive but no parasites were detected by microscopy. This is likely due
to the circulating antigen post treatment. More concerning however are the 14 individuals who
were positive by microscopy but negative by uRDT (0.03%). While this may be a simple
microscopy error (5 of these individuals had a parasite density of <100), an unpublished
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household survey from Uganda has suggested that the prevalence of HRP2 deletions is 1.6%
(25/1493). (25) Genomic analysis will need to be performed to determine if these 14 individuals
had the HRP2 deletion. This loss of the pfhrp2 gene is a cause for concern as HRP2-RDTs
become ubiquitous in malaria diagnosis.

Early detection of a TF is crucial for the quick and timely switch to an alternate second-line antimalarial thus avoiding any severe complications. The day 3 HRP2 concentration has been shown
to indicate eventual recrudescence in individuals post antimalaria treatment. (44) Along the same
lines, in this study, we report a novel ability of the uRDT to predict an upcoming TF 7 days
prior. A study in 2001 also tested the ability of a PfHRP2 dipstick on day 7 and day 14 to predict
TF but found no association. (47, 52) Alere’s more sensitive RDT, compared to its predecessors,
may allow us to reliably anticipate a TF. More research must be done on a larger scale to validate
the accuracy of the uRDT as a TF predictor.

However, we must consider the practical implications of using an RDT as an early signal of TF.
Not only is it infeasible to require individuals to return following AL treatment to test for a
possible TF, there is also the likelihood that the uRDT is positive due to persistence of antigen
and not recrudescence of the parasite. Therefore, we do not recommend implementing the uRDT
on a large scale as an early indicator of TF. Instead, the uRDT should remain for its intended
purpose- as a more sensitive test to eliminate and eradicate malaria in low transmission settings.
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Conclusion and limitations

One of the major limitations of this study is the small sample size used for the analysis. While
the statistical tests account for the small sample size, additional studies need to be done to
support the associations suggested in this study. One of our key hypotheses was that AL regimen
would be associated with treatment outcome. We saw an incidence of treatment failure in 71.7%
of participants in our 3-day AL group and 66.7% in our 5-day group. Using this as a baseline
incidence, to achieve a power of 70% at an alpha of 0.05, we would ideally need >1000 children
in each treatment group. A similar sample size would be needed to understand if HIV status
affects treatment outcome.

Another limitation was that initial diagnosis of malaria was done with microscopy and not
uRDT. This could have limited our study to only those individuals who had a high enough
parasitemia to be microscopically detected. However, it is unlikely that not including low
parasitemia cases in our study would have impacted our results.

Finally, this study used microscopy as the gold standard for malaria detection and diagnosis.
Since LAMP is considered a far more sensitive and accurate measure of malaria parasite
presence, future studies should consider incorporating LAMP into the analysis and potentially as
the gold standard. It would also be interesting to see if LAMP’s ability to predict TF is
comparable to that of the uRDT.
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Overall, the evidence from this study highlight the potential and drawbacks of Alere’s new
uRDT. Its highly sensitive nature means the test is likely to return a positive result long after the
clearance of malaria parasites. Ideally, if the uRDT is used to establish a malaria diagnosis,
physicians should examine prior medical records and take into consideration that the uRDT may
still be positive from a previous malaria infection. Concern over false positive and incorrect
diagnoses recommend that the use of Alere’s uRDT should be limited to low transmission
settings.
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